Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPEP | Q07075 | 3/20 | 0.52 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.48 |
| ▸ | BLM | P54132 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.43 |
| ▸ | GABRP | O00591 | 3/20 | 0.43 |
| ▸ | GABRD | O14764 | 3/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.43 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.43 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.43 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.43 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11981919 | 0.93 | ENPEP (0.53) | ENPEPTSHRNFKB1BLMKMT2A | |
| SCHEMBL258995 | 0.86 | — | — | |
| SCHEMBL859458 | 0.86 | — | — | |
| SCHEMBL68935 | 0.86 | — | — | |
| SCHEMBL28189436 | 0.84 | CYP2D6 (0.61) | ENPEPTSHRNFKB1BLMKMT2A | |
| SCHEMBL7998715 | 0.84 | CYP2D6 (0.61) | ENPEPTSHRNFKB1BLMKMT2A | |
| SCHEMBL11322858 | 0.84 | KMT2A (0.43) | ENPEPTSHRNFKB1BLMKMT2A | |
| Hydrochloric Acid SCHEMBL10636409 | 0.84 | CYP2D6 (0.61) | ENPEPTSHRNFKB1BLMKMT2A | |
| Hydrochloric Acid SCHEMBL31395319 | 0.84 | CYP2D6 (0.61) | ENPEPTSHRNFKB1BLMKMT2A | |
| SCHEMBL15058114 | 0.84 | CYP2D6 (0.61) | ENPEPTSHRNFKB1BLMKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024083919-A1 | INHIBITORS | ZEALAND PHARMA A/S (DK) | 2024-04-25 | — | — | WO | claimed |
| US-20240076328-A1 | KV1.3 BLOCKERS | ZEALAND PHARMA A/S (DK) | 2024-03-07 | — | — | US | claimed |
| CN-114728039-A | Kv1.3 blocking agents | 西兰制药公司 | 2022-07-08 | — | — | CN | claimed |
| WO-2021053194-A1 | KV1.3 BLOCKERS | ZEALAND PHARMA A/S (DK) | 2021-03-25 | — | — | WO | claimed |
| US-20240182531-A1 | KV1.3 Blockers | ZEALAND PHARMA A/S (DK) | 2024-06-06 | — | — | US | disclosed |
| WO-2024083919-A1 | INHIBITORS | ZEALAND PHARMA A/S (DK) | 2024-04-25 | — | — | WO | disclosed |
| US-20240076328-A1 | KV1.3 BLOCKERS | ZEALAND PHARMA A/S (DK) | 2024-03-07 | — | — | US | disclosed |
| EP-4314024-A1 | KV1.3 BLOCKERS | Zealand Pharma A/S (DK) | 2024-02-07 | — | — | EP | disclosed |
| US-11780893-B2 | Kv1.3 blockers | ZEALAND PHARMA A/S (DK) | 2023-10-10 | — | — | US | disclosed |
| US-20230293638-A1 | METHOD OF USING A GIP/GLP1 CO-AGONIST FOR DIABETES | ELI LILLY AND COMPANY | 2023-09-21 | — | — | US | disclosed |
| US-20230143425-A1 | IMPROVEMENTS RELATED TO SORBENT MEDIA | GENESIS SYSTEMS LLC | 2023-05-11 | — | — | US | disclosed |
| CN-114728039-A | Kv1.3 blocking agents | 西兰制药公司 | 2022-07-08 | — | — | CN | disclosed |
| US-20210380646-A1 | KV1.3 BLOCKERS | ZEALAND PHARMA A/S (DK) | 2021-12-09 | — | — | US | disclosed |
| WO-2021053194-A1 | KV1.3 BLOCKERS | ZEALAND PHARMA A/S (DK) | 2021-03-25 | — | — | WO | disclosed |
| EP-1931673-B1 | COMPOUNDS COMPRISING SHORT AMINOALCOHOL CHAINS AND METAL COMPLEXES FOR MEDICAL IMAGING | GUERBET SA (FR) | 2012-08-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11780893-B2 | Kv1.3 blockers | KCNA3, KCNK3, KCNN3 | ENPEP 4089/4885TSHR 2618/4885NFKB1 2436/4885 |
| US-20230293638-A1 | METHOD OF USING A GIP/GLP1 CO-AGONIST FOR DIABETES | GLP1R, GIPR, GCGR | ENPEP 955/4885TSHR 93/4885NFKB1 4193/4885 |
| US-20240076328-A1 | KV1.3 BLOCKERS | KCNA3, KCNK3, KCNN3 | ENPEP 4089/4885TSHR 2618/4885NFKB1 2436/4885 |
| US-20240182531-A1 | KV1.3 Blockers | KCNA3, KCNK3, KCNN3 | ENPEP 4089/4885TSHR 2618/4885NFKB1 2436/4885 |
| US-20210380646-A1 | KV1.3 BLOCKERS | KCNA3, KCNK3, KCNN3 | ENPEP 4089/4885TSHR 2618/4885NFKB1 2436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.